| Literature DB >> 35268738 |
Yerlan M Suleimen1,2, Rani A Jose3,4, Raigul N Suleimen5, Christoph Arenz6, Margarita Y Ishmuratova7, Suzanne Toppet3, Wim Dehaen3, Bshra A Alsfouk8, Eslam B Elkaeed9, Ibrahim H Eissa10, Ahmed M Metwaly11,12.
Abstract
A new flavonoid, Jusanin, (1) has been isolated from the aerial parts of Artemisia commutata. The chemical structure of Jusanin has been elucidated using 1D, 2D NMR, and HR-Ms spectroscopic methods to be 5,2',4'-trihydroxy-6,7,5'-trimethoxyflavone. Being new in nature, the inhibition potential of 1 has been estimated against SARS-CoV-2 using different in silico techniques. Firstly, molecular similarity and fingerprint studies have been conducted for Jusanin against co-crystallized ligands of eight different SARS-CoV-2 essential proteins. The studies indicated the similarity between 1 and X77, the co-crystallized ligand SARS-CoV-2 main protease (PDB ID: 6W63). To confirm the obtained results, a DFT study was carried out and indicated the similarity of (total energy, HOMO, LUMO, gap energy, and dipole moment) between 1 and X77. Accordingly, molecular docking studies of 1 against the target enzyme have been achieved and showed that 1 bonded correctly in the protein's active site with a binding energy of -19.54 Kcal/mol. Additionally, in silico ADMET in addition to the toxicity evaluation of Jusanin against seven models have been preceded and indicated the general safety and the likeness of Jusanin to be a drug. Finally, molecular dynamics simulation studies were applied to investigate the dynamic behavior of the Mpro-Jusanin complex and confirmed the correct binding at 100 ns. In addition to 1, three other metabolites have been isolated and identified to be сapillartemisin A (2), methyl-3-[S-hydroxyprenyl]-cumarate (3), and β-sitosterol (4).Entities:
Keywords: ADMET; Artemisia commutata; COVID-19 main protease; DFT; Jusanin; molecular docking; molecular dynamic simulations; molecular similarity; new flavonoid; toxicity
Mesh:
Substances:
Year: 2022 PMID: 35268738 PMCID: PMC8911936 DOI: 10.3390/molecules27051636
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
1H and 13C spectral data of Jusanin (DMSO).
| Position | 1H ( | 13С | Position | 1H ( | 13С |
|---|---|---|---|---|---|
| 2 | 161.97 | 2′ | 152.4 | ||
| 3 | 7.11 s | 106.71 | 3′ | 6.58 s | 104.39 |
| 4 | 182.22 | 4′ | 142.0 | ||
| 5 | 152.6 | 5′ | 139.7 | ||
| 6 | 131.7 | 6′ | 7.45 s | 111.94 | |
| 7 | 158.45 | 6-OCH3 | 3.74 s | 60.0 | |
| 8 | 6.97 s | 91.57 | 7-OCH3 | 3.82 s | 56.7 |
| 9 | 151.95 | 4′-OCH3 | 3.94 s | 56.5 | |
| 10 | 105.3 | 5-OH | 13.06 s | ||
| 1′ | 107.24 |
Figure 1The chemical structure of Jusanin (1).
Figure 2Key HMBC correlations in Jusanin.
Figure 3Chemical structures of compounds 2–4.
Figure 4The chemical structures of co-crystallized ligands of SARS-Cov-2 proteins and Jusanin (the isolated flavonoid).
Figure 5The results of the similarity analysis of Jusanin.
Structural properties of Jusanin and the different co-crystallized ligands of SARSCoV-2 proteins.
| Compound | ALog p | M. Wt | HBA | HBD | Rotatable Bonds | Rings | Aromatic Rings | MFPSA | Minimum Distance |
|---|---|---|---|---|---|---|---|---|---|
|
| 2.361 | 360.315 | 8 | 3 | 4 | 3 | 2 | 0.325 | 0 |
|
| 2.622 | 403.477 | 4 | 2 | 6 | 4 | 3 | 0.22 | 0.92 |
|
| 3.647 | 304.386 | 2 | 2 | 3 | 3 | 3 | 0.171 | 0.95 |
|
| 0.711 | 233.263 | 3 | 1 | 2 | 2 | 1 | 0.237 | 1.10 |
|
| −1.502 | 371.243 | 11 | 5 | 4 | 3 | 2 | 0.612 | 1.12 |
|
| −4.254 | 399.445 | 9 | 4 | 7 | 3 | 2 | 0.483 | 1.17 |
|
| 2.171 | 218.295 | 2 | 1 | 3 | 2 | 1 | 0.179 | 1.20 |
|
| 2.453 | 680.791 | 8 | 5 | 18 | 3 | 2 | 0.273 | 1.38 |
|
| 0.231 | 631.884 | 8 | 6 | 12 | 4 | 0 | 0.256 | 1.52 |
Fingerprint similarity between Jusanin and the different co-crystallized ligands of SARSCoV-2 proteins.
| Comp. | Similarity | SA | SB | SC |
|---|---|---|---|---|
| Jusanin | 1 | 331 | 0 | 0 |
|
| 0.512 | 266 | 188 | 65 |
|
| 0.489 | 258 | 196 | 73 |
|
| 0.436 | 151 | 15 | 180 |
|
| 0.339 | 136 | 70 | 195 |
|
| 0.310 | 120 | 56 | 211 |
|
| 0.299 | 131 | 106 | 200 |
|
| 0.291 | 327 | 789 | 4 |
|
| 0.138 | 216 | 1231 | 115 |
Figure 6Flexible alignment of Jusanin (green) with X77 (pink).
MO spatial distribution of Jusanin and X77.
| Name | Binding Energy (Ha) | HOMO Energy (Ha) | LUMO Energy (Ha) | Dipole Mag | Band Gap Energy (Ha) |
|---|---|---|---|---|---|
| Jusanin | −8.558 | −0.180 | −0.098 | 2.395 | 0.083 |
|
| −10.830 | −0.158 | −0.062 | 2.906 | 0.096 |
Figure 7MO spatial distribution of (A) Jusanin and (B) X77.
Figure 8MEP map of (A) X77 and (B) Jusanin.
Figure 9Superimposition of the docking pose (dark green) and the co-crystallized (pink) of the same molecule.
Figure 10(A) Three-dimensional, (B) two-dimensional, and (C) surface mapping of X77 docked into Mpro.
Predicted ADMET for Jusanin and reference.
| Comp. | BBB Level a | Solubility Level | Absorption Level | CYP2D6 Prediction b | PPB Prediction c |
|---|---|---|---|---|---|
| Jusanin | V. low | good | good | non inhibitor | >90% |
| Simeprevir | V. low | low | V. poor | non inhibitor | >90% |
a BBB level, blood–brain barrier penetration level; b CYP2D6, cytochrome P2D6 inhibition; c PBB, plasma protein binding level.
Figure 11(A) Three-dimensional, (B) two-dimensional, and (C) surface mapping of Jusanin docked into Mpro.
Figure 12The expected ADMET study. ADMET_AlogP98: lipid-water partition coefficient; ADMET_PSA_2D: polar molecular surface area. Two-dimensional polar surface area (PSA_2D) each drug is plotted against their computed atom-type partition coefficient (ALogP98). The area encompassed by the ellipse represents good absorption without any violation of the ADMET properties. Based on Egan et al. [75] absorption model the 95% and 99% confidence limit ellipses corresponding to the blood–brain barrier (BBB) and intestinal absorption models are indicated.
Toxicity properties of Jusanin and reference.
| Comp. | FDA Rodent Carcinogenicity | Carcinogenic Potency TD50 | Rat Maximum Tolerated Dose | Rat Oral LD50 b | Rat Chronic LOAEL b | Ocular Irritancy | Skin Irritancy |
|---|---|---|---|---|---|---|---|
| Jusanin | Non-Carcinogen | 13.5782 | 0.3502 | 0.4621 | 0.0624 | Mild | Non-Irritant |
| Simeprevir | Non-Carcinogen | 0.2803 | 0.0030 | 0.2088 | 0.0021 | Mild | Non-Irritant |
a Unit: mg/kg body weight/day b Unit: g/kg body weight.
Figure 13Molecular dynamics simulations results; (A) RMSD values of Jusanin, Mpro, and Jusanin-Mpro complex during MD runs. (B) RMSF for Mpro in the MD run. (C) Radius of gyration of Mpro in the MD run. (D) SASA of Mpro in the MD run. (E) H-bonding between Jusanin-Mpro complex in the MD run.